50值分別為(22.1±4.6)、(19.2±1.2)μg/mL,體內(nèi)抑瘤率為(35.4±18.8)%。結(jié)論 將舒林酸制備成納米粒后,拓寬了舒林酸的給藥途徑,顯著增強(qiáng)其抗腫瘤作用。;Objective To prepare sulindac nanosuspensions, and study its anti-tumor effect. Methods Sulindac nanosuspensions were prepared with sodium oleate as stabilizer. The quality of nanosuspension was evaluated by particle size, dispersion index (PDI), potential and electron micrograph morphology. MTT colorimetric assay and MCF-7 cells and 4T1 were used for in vitro antitumor effect, and 4T1 tumor-bearing mice were used for anti-tumor effect in vivo. Results The shape of sulindac nanosuspensions was spherical, the PDI value was less than 0.3, and the particle size was (264.1±2.9) nm. The anti-tumor effect was significantly improved compared with the drug substance in vitro and the IC50 values for MCF-7 and 4T1 were (22.1±4.6) and (19.2±1.2) μg/mL. Tumor inhibition rate in vivo was (35.4±18.8)%. Conclusion The preparation of sulindac into nanoparticles by nano preparation technology broadened the drug delivery pathway of sulindac and significantly enhanced the anti-tumor effect."/>